Cogent Biosciences Inc (COGT)

NASDAQ
Currency in USD
7.315
+0.025(+0.34%)
Real-time Data
COGT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
7.1507.315
52 wk Range
5.73012.610
Cogent Biosciences Inc is currently considered to be trading at Fair valueExplore our list of undervalued stocks for hidden opportunities
Key Statistics
Edit
Prev. Close
7.29
Open
7.23
Day's Range
7.15-7.315
52 wk Range
5.73-12.61
Volume
388.8K
Average Volume (3m)
1.32M
1-Year Change
6.73%
Book Value / Share
1.32
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COGT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
16.500
Upside
+125.56%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Cogent Biosciences Inc Company Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Compare COGT to Peers and Sector

Metrics to compare
COGT
Peers
Sector
Relationship
P/E Ratio
−3.1x−1.1x−0.5x
PEG Ratio
1.57−0.010.00
Price/Book
5.4x0.6x2.6x
Price / LTM Sales
-61.8x3.0x
Upside (Analyst Target)
119.5%537.6%54.1%
Fair Value Upside
Unlock13.1%9.4%Unlock

Analyst Ratings

8 Buy
3 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 16.500
(+125.56% Upside)

Earnings

Latest Release
Feb 25, 2025
EPS / Forecast
-0.61 / -0.61
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Cogent Biosciences (COGT) Stock Price Today?

The Cogent Biosciences stock price today is 7.315

What Stock Exchange Does Cogent Biosciences Trade On?

Cogent Biosciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Cogent Biosciences?

The stock symbol for Cogent Biosciences is "COGT."

What Is the Cogent Biosciences Market Cap?

As of today, Cogent Biosciences market cap is 801.41M.

What is Cogent Biosciences Earnings Per Share?

The Cogent Biosciences EPS is -2.46.

What Is the Next Cogent Biosciences Earnings Date?

Cogent Biosciences will release its next earnings report on 12 May 2025.

From a Technical Analysis Perspective, Is COGT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.